Luteanine (Isocorydine) exhibits antiarrhythmic, vasodilatory, and anti-hypoxic effects; it demonstrates significant potential in combination with doxorubicin (DOX) for the eradication of hepatocellular carcinoma (HCC) by enhancing cytotoxicity, reversing DOX-induced epithelial-mesenchymal transition (EMT), and inhibiting tumor growth in vivo.